Inhibitor Report for: Galanthamine
Galanthamine | Type (5) |
| Other_Name (6) |
| Chemical_Nomenclature | 1,2,3,4,6,7,7a,11c-octahydro-9-methoxy-2methylbenzofuro[4,3,2-efg][2]benzazocin-6-ol |
| Formula | C17H21NO3 |
| CAS_number | 357-70-0 |
| MW | 287.35 |
| |
| Paper (45) |
| Structure | 1DX6 |
| | 1QTI |
| | 1W6R |
| | 1W76 |
| | 4EY6 |
| Comment | In 1951, the Russian pharmacologist Mikhail Mashkovsky discovered that local villagers from the Urals used the wild snowdrop (Galanthus spp., most notably Galanthus woronowii Losinsk.) to stave off paralysis in children suffering from poliomyelitis. The ethnobotanical use of the snowdrop in the Urals led to the isolation of galanthamine for the first time in 1952, an alkaloid with AChE-inhibiting propertiesAlkaloid from caucasian snow-drop Galenthus woronowii, the common snowdrop Galanthus nivalis Ungernia genus, Amaryllidaceae, from Narcissus spp. Selectivity for AChE. The CAS number of Galanthamine Hydrobromide is 1953-04-4. |
| | Nivalin Reminyl trademark approved for treatment of Alzheimer disease in Austria. |
| | Galantamine is a specific competitive and reversible aceylcholinesterase inhibitor. It is also an allosteric modulator at nicotinic cholinergic receptor sites potentiating cholinergic nicotinic neurotransmission at the ganglionic and the neuromuscular junctions. |
| Gene_locus | torca-ACHE |
| | human-ACHE |
| CID | 9651 |
| Family | ACHE |
| InChIKey | ASUTZQLVASHGKV-JDFRZJQESA-N |
| CanonicalSMILES | CN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O |
| InChI | InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1 |
| IupharLig | 6693 |
| Wikipedia | Galanthamine |
|
|